Rigel Pharmaceuticals Inc. company information, Employees & Contact Information

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire

First patient enrolled: Rigel advances R289 Phase 1b dose expansion, 500 mg qd/bid, up to 40 pts for RP2D Stock Titan

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors Quantisnow

41,138 Options & 27,475 RSUs — Rigel Announces Inducement Grants to New Employees Stock Titan

Biotech Leader Rigel Pharmaceuticals Announces Packed September Schedule with 4 Major Healthcare Conferences Stock Titan

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire

Biotech Rigel Pharmaceuticals Reveals Q2 2025 Earnings Date: Key Financial Results Coming August 5 Stock Titan

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation PR Newswire

Rigel Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 Stock Titan

Rigel Provides Business Update and 2025 Outlook PR Newswire

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease PR Newswire

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS PR Newswire

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS PR Newswire

Rigel Pharmaceuticals Provides Business Update PR Newswire

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR Newswire

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition PR Newswire

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS PR Newswire

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress PR Newswire

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML PR Newswire

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan PR Newswire

Rigel Announces Reverse Stock Split PR Newswire

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® PR Newswire

Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation PR Newswire

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire

Rigel Appoints Kamil Ali-Jackson to Board of Directors PR Newswire

Rigel Announces Closing of Strategic Collaboration with Lilly PR Newswire

Rigel at H.C. Wainwright Conference: Strategic Growth and Pipeline Focus Investing.com

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia PR Newswire

Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients Business Wire

Company warns about risk for severe infections with drug approved for lung, thyroid cancers Healio

Optimization of Pharmacokinetic and In Vitro Safety Profile of a Series of Pyridine Diamide Indirect AMPK Activators ACS Publications

Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe PR Newswire

Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries PR Newswire

Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S. PR Newswire

RIGL - Rigel Pharmaceuticals Inc Latest Stock News & Market Updates Stock Titan

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases PR Newswire

Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) MultiVu

Blue-white Rigel is Orion’s brightest star EarthSky

Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD) Wiley Online Library

Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD) Wiley Online Library

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis MarketBeat